Referências

  1. Organização Pan-Americana da Saúde. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacosensible. Washington, D.C.: OPAS; 2023. Disponível em: https://iris.paho.org/handle/10665.2/57619.
  2. Organização Mundial da Saúde. WHO operational handbook on tuberculosis Module 4: Treatment – tuberculosis care and support. Genebra: OMS; 2022. Disponível em: https://www.who.int/publications/i/item/9789240053519.
  3. Organização Mundial da Saúde. The End TB Strategy (WHO/HTM/TB/2015.19). Genebra: OMS; 2015. Disponível em: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19.
  4. Organização Pan-Americana da Saúde. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 3: Diagnóstico. Métodos de diagnóstico rápido para la detección de la tuberculosis, 2022. Washington, D.C.: OPAS; 2021. Disponível em: https://iris.paho.org/handle/10665.2/55926.
  5. Organização Mundial da Saúde. Global tuberculosis report 2021. Genebra: OMS; 2021. Disponível em: https://www.who.int/publications/i/item/9789240037021.
  6. Ismail NA, Mvusi L, Nanoo A, Dreyer A, Omar SV, Babatunde S et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. Lancet Infect Dis. 2018;18(7):779–87. Disponível em: https://www.researchgate.net/publication/324677816_Prevalence_of_drug-resistant_tuberculosis_and_imputed_burden_in_South_Africa_a_national_and_sub-national_cross-sectional_survey.
  7. Kayomo MK, Mbula VN, Aloni M, André E, Rigouts L, Boutachkourt F et al. Targeted next-generation sequencing of sputum for diagnosis of drug-resistant TB: results of a national survey in Democratic Republic of the Congo. Sci Rep. 2020;10(1):10786. Disponível em: https://www.nature.com/articles/s41598-020-67479-4.
  8. Lim DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, Cabibbe AM, Zignol M et al. Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. Eur Respir J. 2018;51(3):1702571. Disponível em: https://pubmed.ncbi.nlm.nih.gov/29496754/.
  9. Mesfin AB, Araia ZZ, Beyene HN, Mebrahtu AH, Suud NN, Berhane YM et al. First molecular based anti-TB drug resistance survey in Eritrea. Int J Tuberc Lung Dis. 2021;25(1):43–51. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33384044/.
  10. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185–92. Disponível em: https://www.em-consulte.com/article/1081233/population-based-resistance-of-mycobacterium-tuber.
  11. Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974034/.
  12. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000150. Disponível em: https://pubmed.ncbi.nlm.nih.gov/20101802/.
  13. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011;53(4):369–72. Disponível em: https://pubmed.ncbi.nlm.nih.gov/21810750/.
  14. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007–2009. Int J Tuberc Lung Dis. 2012;16(6):812–6. Disponível em: https://pubmed.ncbi.nlm.nih.gov/22507372/.
  15. Namugenyi J, Musaazi J, Katamba A, Kalyango J, Sendaula E, Kambugu A et al. Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study. BMC Infect Dis. 2021;21(1):513. Disponível em: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06220-6.
  16. Parceria Stop TB. Step Up for TB 2020. Genebra: Parceria Stop TB; 2020. Disponível em: https://www.stoptb.org/advocate-to-endtb/step-tb-suft-project.
  17. Cazabon D, Pande T, Kik S, Van Gemert W, Sohn H, Denkinger C et al. Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: a trend analysis from 2014 - 2016. Gates Open Res. 2018;2:35. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139378/.
  18. Organização Pan-Americana da Saúde. Manual operativo de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Washington, D.C.: OPAS; 2020. Disponível em: https://iris.paho.org/handle/10665.2/55997.
  19. Organização Mundial da Saúde. Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. Geneva: Organização Mundial da Saúde; 2014. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf.
  20. Organização Pan-Americana da Saúde. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 5: Manejo de la tuberculosis en la población infantil y adolescente. Washington, D.C.: OPAS; 2023. Disponível em: https://iris.paho.org/handle/10665.2/57408.
  21. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231–79. Disponível em: https://pubmed.ncbi.nlm.nih.gov/10529902/.
  22. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621–9. Disponível em: https://pubmed.ncbi.nlm.nih.gov/20797644/.
  23. Organização Mundial da Saúde. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Genebra: OMS; 2016. Disponível em: https://apps.who.int/iris/handle/10665/208825.
  24. Modongo C, Wang Q, Dima M, Matsiri O, Kgwaadira B, Rankgoane-Pono G et al. Clinical and virological outcomes of TB/HIV coinfected patients treated with dolutegravir-based HIV antiretroviral regimens: programmatic experience from Botswana. J Acquir Immune Defic Syndr. 2019;82(2):111–5. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794061/.
  25. Alffenaar J-WC, Akkerman OW, Bothamley G. Monitoring during and after tuberculosis treatment. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:308–25. Disponível em: https://doi.org/10.1183/2312508X.10022217.
  26. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577– 87. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa1407426.
  27. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–98. Disponível em: https://pubmed.ncbi.nlm.nih.gov/25337748/.
  28. Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–608. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa1314210.
  29. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705–18. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33951360/.
  30. Organização Pan-Americana da Saúde. Manual operativo de la OMS sobre la tuberculosis. Módulo 5: Manejo de la tuberculosis en la población infantil y adolescente. Washington, D.C.: OPAS; 2023. Disponível em: https://iris.paho.org/handle/10665.2/57447.
  31. Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med. 2022;386(10):911–22. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35263517/.
  32. Organização Pan-Americana da Saúde. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 1: Prevención. Tratamiento preventivo de la tuberculosis. Washington, D.C.: OPAS; 2022. Disponível em: https://iris.paho.org/handle/10665.2/55801.
  33. Organização Mundial da Saúde. Directriz: actualizaciones sobre la atención de la desnutrición aguda severa en lactantes y niños. Genebra: OMS; 2016 https://apps.who.int/iris/handle/10665/249206.
  34. Organização Pan-Americana da Saúde. Definición de la OMS de caso de infección por el VIH a efectos de vigilancia y revisión de la estadificación clínica y de la clasificación inmunológica de la enfermedad relacionada con el VIH en adultos y niños. Washington D. C.: OPAS; 2009. Disponível em: https://www.paho.org/hq/dmdocuments/2009/DEFINICION_ESTADIFICACION2.pdf.
  35. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50(9):1288– 99. Disponível em: https://pubmed.ncbi.nlm.nih.gov/20353364/.
  36. Organização Mundial da Saúde. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Genebra: OMS; 2017. Disponível em: https://apps.who.int/iris/handle/10665/255052.
  37. Organização Mundial da Saúde. Política de la OMS sobre actividades de colaboración TB/VIH: Guías para programas nacionales y otros interesados directos (directrices de la OMS aprobadas por el Comité de Examen de Directrices). Genebra: OMS; 2012. Disponível em: https://iris.who.int/handle/10665/44838.
  38. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379(20):1915–25. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30428290/.
  39. Holden IK, Lillebaek T, Andersen PH, Bjerrum S, Wejse C, Johansen IS. Extrapulmonary tuberculosis in Denmark from 2009 to 2014; characteristics and predictors for treatment outcome. Open Forum Infect Dis. 2019;6(10):ofz388. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31660351/.
  40. Bruchfeld J, Forsman LD, Fröberg G, Niward K. Extrapulmonary tuberculosis. In: Migliori GB & Raviglione MC (eds.), Essential tuberculosis. Switzerland: Springer, Cham; 2021:259–66. Disponível em: https://link.springer.com/chapter/10.1007/978-3-030-66703-0_29.
  41. Fontanilla J-M, Barnes A, von Reyn CF. Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis. 2011;53(6):555–62. Disponível em: https://pubmed.ncbi.nlm.nih.gov/21865192/.
  42. Rieder HL. Epidemiological basis of tuberculosis control. Paris: International Union Against Tuberculosis and Lung Disease; 1999. Disponível em: https://tbrieder.org/publications/books_english/epidemiology_en.pdf.
  43. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e95. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27516382/.
  44. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control (National Institute for Health and Clinical Excellence: Guidance). Londres: National Collaborating Centre for Chronic Conditions; 2006. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27516382/.
  45. Sociedade Torácica Americana, Centros de Controle e Prevenção de Doenças dos EUA, Sociedade Americana de Doenças Infecciosas. Treatment of tuberculosis. Am J Resp Crit Care Med 2003;167:603--62. Disponível em: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm.
  46. Organização Mundial da Saúde. Treatment of tuberculosis: guidelines for national programmes, 4th edition. Genebra: OMS; 2010. Disponível em: https://apps.who.int/iris/handle/10665/44165.
  47. Chotmongkol V, Jitpimolmard S, Thavornpitak Y. Corticosteroid in tuberculous meningitis. J Med Assoc Thai. 1996;79(2):83–90. Disponível em: https://pubmed.ncbi.nlm.nih.gov/8868018/.
  48. Kumarvelu S, Prasad K, Khosla A, Behari M, Ahuja GK. Randomized controlled trial of dexamethasone in tuberculous meningitis. Int J Tuberc Lung Dis. 1994;75(3):203–7. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/0962847994900094.
  49. Malhotra HS, Garg RK, Singh MK, Agarwal A, Verma R. Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis. Ann Trop Med Parasitol. 2009;103(7):625–34. Disponível em: https://pubmed.ncbi.nlm.nih.gov/19825284/.
  50. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226–31. Disponível em: https://pubmed.ncbi.nlm.nih.gov/9024451/.
  51. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TTO, Nguyen TCT et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–51. Disponível em: https://pubmed.ncbi.nlm.nih.gov/15496623/.
  52. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2002;(4):CD000526. Disponível em: https://pubmed.ncbi.nlm.nih.gov/12519546/.
  53. Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):223–37. Disponível em: https://pubmed.ncbi.nlm.nih.gov/23369413/.
  54. Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121–30. Disponível em: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1407380.
  55. Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart. 2000;84(2):183–8. Disponível em: https://pubmed.ncbi.nlm.nih.gov/10908256/.
  56. Reuter H, Burgess LJ, Louw VJ, Doubell AF. Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovasc J S Afr. 2006;17(5):233–8. Disponível em: https://pubmed.ncbi.nlm.nih.gov/17117227/.
  57. Schrire V. Experience with pericarditis at Groote Schuur Hospital, Cape Town: an analysis of one hundred and sixty cases studied over a six-year period. S Afr Med J. 1959;33:810–7. Disponível em: https://pubmed.ncbi.nlm.nih.gov/14443596/.
  58. Strang JI, Kakaza HH, Gibson DG, Allen BW, Mitchison DA, Evans DJ et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet. 1988;2(8614):759–64. Disponível em: https://pubmed.ncbi.nlm.nih.gov/2901610/.
  59. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet. 1987;2(8573):1418–22. Disponível em: https://pubmed.ncbi.nlm.nih.gov/2891992/.
  60. GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018;18(3):261–84. Disponível em: https://researchonline.jcu.edu.au/54740/.
  61. Magis-Escurra C, Carvalho ACC, Kritski AL, Girardi E. Comorbidities. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:276–90. Disponível em: https://doi.org/10.1183/2312508X.10022017.
  62. Tiberi S, Pontali E, Tadolini M, D’Ambrosio L, Migliori GB. Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. Int J Infect Dis. 2019;80S:S68–S72. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30690212/.
  63. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care. 2012;185(7):779–84. Disponível em: https://www.atsjournals.org/doi/10.1164/rccm.201106-1083OC.
  64. Nguenha D, Acacio S, Murias-Closas A, Ramanlal N, Saavedra B, Karajeanes E et al. Prevalence and clinical characteristics of pulmonary tuberculosis among pregnant and post-partum women. Int J Tuberc Lung Dis. 2022;26(7):641-9. Disponível em: https://doi.org/10.5588/ijtld.21.0567.
  65. Jana N, Barik S, Arora N, Singh AK. Tuberculosis in pregnancy: the challenges for South Asian countries. J Obstet Gynaecol Res. 2012;38(9):1125–36. Disponível em: https://pubmed.ncbi.nlm.nih.gov/22563776/.
  66. LaCourse SM, Greene SA, Dawson-Hahn EE, Hawes SE. Risk of adverse infant outcomes associated with maternal tuberculosis in a low burden setting: a population-based retrospective cohort study. Infect Dis Obstet Gynecol. 2016;2016:6413713. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771913/.
  67. Chang C-W, Wu PW, Yeh C-H, Wong K-S, Wang C-J, Chang C-C. Congenital tuberculosis: case report and review of the literature. Paediatr Int Child Health. 2018;38(3):216–9. Disponível em: https://pubmed.ncbi.nlm.nih.gov/28421876/.
  68. Sulis G, Gnanou S, Roggi A, Konseimbo A, Giorgetti PF, Castelli F et al. Active tuberculosis case finding among pregnant women: a pilot project in Burkina Faso. Int J Tuberc Lung Dis. 2016;20(10):1306–8. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27725039/.
  69. Caminero JA, Scardigli A, van der Werf T, Tadolini M. Treatment of drug-susceptible and drug-resistant tuberculosis. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:152–78. Disponível em: https://research.rug.nl/en/publications/treatment-of-drug-susceptible-and-drug-resistant-tuberculosis.
  70. Caminero JA, Lasserra P, Piubello A. Adverse anti-tuberculosis drug events and their management. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:205–27. Disponível em: https://doi.org/10.1183/2312508X.10021617.
  71. Schaaf HS, Marais BJ, Carvalho I. Challenges in childhood tuberculosis. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:234– 62. Disponível em: https://www.ers-education.org/lr/show-details/?idP=214582.
  72. Repossi A, Bothamley G. Tuberculosis in pregnancy and the elderly. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:263–75. Disponível em: https://www.ers-education.org/lr/show-details/?idP=214583.
  73. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93–e142. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31729908/.
  74. Kawatsu L, Yoshiyama T, Kato S. Tuberculosis in the elderly. In: Migliori GB & Raviglione MC (eds.), Essential Tuberculosis. Cham, Switzerland: Springer; 2021:253–8. Disponível em: https://link.springer.com/chapter/10.1007/978-3-030-66703-0_28.
  75. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med. 1985;312(23):1483–7. Disponível em: https://pubmed.ncbi.nlm.nih.gov/3990748/.
  76. Centros de Controle e Prevenção de Doenças dos EUA. Prevention and control of tuberculosis in facilities providing long-term care to the elderly. Recommendations of the Advisory Committee for Elimination of Tuberculosis. Morbidity and Mortality Weekly Report, US: CDC; 1990. Disponível em: https://www.cdc.gov/mmwr/preview/mmwrhtml/00001711.htm.
  77. Institute for Health Metrics Evaluation. Global burden of disease [internet]. Institute for Health Metrics Evaluation; 2019. Disponível em: https://www.healthdata.org/research-analysis/gbd.
  78. Department of Epidemiology and Clinical Research [internet]. Tokyo: The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association; 2022. Disponível em: https://jata.or.jp/english/decr.html.
  79. Lin H-S, Cheng C-W, Lin M-S, Chou Y-L, Chang P-J, Lin J-C et al. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. Clin Interv Aging. 2016;11:299–306. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795580/.
  80. Yoshiyama T. Tuberculosis treatment for patients more than 80 years old. Kekkaku: [Tuberculosis]. 2017;92(7):485–91. Disponível em: https://www.researchgate.net/publication/320857126_ Tuberculosis_treatment_for_patients_more_than_eighty_years_old.
  81. Igari H, Imasawa T, Noguchi N, Nagayoshi M, Mizuno S, Ishikawa S et al. Advanced stage of chronic kidney disease is risk of poor treatment outcome for smear-positive pulmonary tuberculosis. J Infect Chemother. 2015;21(8):559–63. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26048063/.
  82. Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin Pharmacokinet. 2005;44(3):221–35. Disponível em: https://pubmed.ncbi.nlm.nih.gov/15762766/.
  83. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173–84. Disponível em: https://pubmed.ncbi.nlm.nih.gov/17630041/.
  84. Matsumoto K, Komukai J, Kasai S, Hirota S, Koda S, Terakawa K et al. [Evaluation of risk factors for failed/defaulted on treatment outcomes of pulmonary tuberculosis in Osaka City]. Kekkaku: [Tuberculosis]. 2014;89(6):593–9. Disponível em: https://pubmed.ncbi.nlm.nih.gov/25095644/.
  85. Palmero D, Mendoza A. Clinical and programmatic aspects of kidney and liver failure and its impact on tuberculosis. In: Migliori GB & Raviglione MC (eds.), Essential Tuberculosis. Cham, Switzerland: Springer; 2021:267–74. Disponível em: https://link.springer.com/chapter/10.1007/978-3-030-66703-0_30.
  86. Organização Mundial da Saúde. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2014.11). Genebra: OMS; 2015. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_eng.pdf.
  87. Sonika U, Kar P. Tuberculosis and liver disease: management issues. Trop Gastroenterol. 2012;33(2):102–6. Disponível em: https://pubmed.ncbi.nlm.nih.gov/23025055/.
  88. Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol. 2012;2(3):260–70. Disponível em: https://pubmed.ncbi.nlm.nih.gov/25755442/.
  89. Bosch A, Valour F, Dumitrescu O, Dumortier J, Radenne S, Pages-Ecochard M et al. A practical approach to tuberculosis diagnosis and treatment in liver transplant recipients in a low-prevalence area. Med Mal Infect. 2019;49(4):231–40. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30591271/.
  90. Caminero JA, Migliori GB. Rationale for anti-tuberculosis chemotherapy. In: Migliori GB & Raviglione MC (eds.), Essential Tuberculosis. Cham, Suíça: Springer; 2021:109–20. Disponível em: https://doi.org/10.1007/978-3-030-66703-0_12.
  91. Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92S:S15–S25. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32032752/.
  92. Organização Pan-Americana da Saúde. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Washington, D.C.: OPAS; 2022. Disponível em: https://iris.paho.org/handle/10665.2/56062.
  93. Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC et al. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016;48(4):1160–70. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27587552/.
  94. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32636299/.
  95. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640–5. Disponível em: https://pubmed.ncbi.nlm.nih.gov/15971391/.
  96. Organização Pan-Americana da Saúde. Directrices para el manejo programático de la tuberculosis drogorresistente, actualización del 2011. Washington D. C.: OPAS; 2011. Disponível em: https://www.paho.org/es/documentos/directrices-para-manejo-programatico-tuberculosis-drogorresistente-2011.
  97. Organização Mundial da Saúde. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17–19 November 2020. Genebra: OMS; 2021. Disponível em: https://apps.who.int/iris/handle/10665/340284.
  98. Linh NN, Viney K, Gegia M, Falzon D, Glaziou P, Floyd K et al. Organização Mundial da Saúde treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021;58(2):2100804. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34413124/.
  99. Avaliani Z, Gozalov O, Kuchukhidze G, Skrahina A, Soltan V, van den Boom M et al. What is behind programmatic treatment outcome definitions for tuberculosis? Eur Clin Respir J. 2020;56(1):2001751. Disponível em: https://erj.ersjournals.com/content/56/1/2001751.
  100. Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021;25(10):797–813. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34615577/.

Book navigation